Cargando…

Correlation of HOXD3 promoter hypermethylation with clinical and pathologic features in screening prostate biopsies

BACKGROUND: Molecular markers that can discriminate indolent cancers from aggressive ones may improve the management of prostate cancer and minimize unnecessary treatment. Aberrant DNA methylation is a common epigenetic event in cancers and HOXD3 promoter hypermethylation (H3PH) has been found in pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Leonard N, Rubin, Rachel S, Othepa, Eugide, Cer, Caroline, Yun, Elizabeth, Agarwal, Raghunath P, Collins, Brian T, McGeagh, Kevin, Pahira, John, Bandi, Guarav, Kowalczyk, Keith, Kumar, Deepak, Dritschilo, Anatoly, Collins, Sean P, Bostwick, David G, Lynch, John H, Suy, Simeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4285328/
https://www.ncbi.nlm.nih.gov/pubmed/24847526
http://dx.doi.org/10.1002/pros.22790
_version_ 1782351570685394944
author Chen, Leonard N
Rubin, Rachel S
Othepa, Eugide
Cer, Caroline
Yun, Elizabeth
Agarwal, Raghunath P
Collins, Brian T
McGeagh, Kevin
Pahira, John
Bandi, Guarav
Kowalczyk, Keith
Kumar, Deepak
Dritschilo, Anatoly
Collins, Sean P
Bostwick, David G
Lynch, John H
Suy, Simeng
author_facet Chen, Leonard N
Rubin, Rachel S
Othepa, Eugide
Cer, Caroline
Yun, Elizabeth
Agarwal, Raghunath P
Collins, Brian T
McGeagh, Kevin
Pahira, John
Bandi, Guarav
Kowalczyk, Keith
Kumar, Deepak
Dritschilo, Anatoly
Collins, Sean P
Bostwick, David G
Lynch, John H
Suy, Simeng
author_sort Chen, Leonard N
collection PubMed
description BACKGROUND: Molecular markers that can discriminate indolent cancers from aggressive ones may improve the management of prostate cancer and minimize unnecessary treatment. Aberrant DNA methylation is a common epigenetic event in cancers and HOXD3 promoter hypermethylation (H3PH) has been found in prostate cancer. Our objective was to evaluate the relationship between H3PH and clinicopathologic features in screening prostate biopsies. METHODS: Ninety-two patients who underwent a prostate biopsy at our institution between October 2011 and May 2012 were included in this study. The core with the greatest percentage of the highest grade disease was analyzed for H3PH by methylation-specific PCR. Correlational analysis was used to analyze the relationship between H3PH and various clinical parameters. Chi-square analysis was used to compare H3PH status between benign and malignant disease. RESULTS: Of the 80 biopsies with HOXD3 methylation status assessable, 66 sets were confirmed to have cancer. In the 14 biopsies with benign disease there was minimal H3PH with the mean percentage of methylation reference (PMR) of 0.7%. In contrast, the HOXD3 promoter was hypermethylated in 16.7% of all cancers and in 50% of high risk tumors with an average PMR of 4.3% (P = 0.008). H3PH was significantly correlated with age (P = 0.013), Gleason score (P = 0.031) and the maximum involvement of the biopsy core (P = 0.035). CONCLUSIONS: H3PH is associated with clinicopathologic features. The data indicate that H3PH is more common in older higher risk patients. More research is needed to determine the role of this marker in optimizing management strategies in men with newly diagnosed prostate cancer. Prostate 74:714–721, 2014. © 2014 The Authors. The Prostate published by Wiley Periodicals, Inc.
format Online
Article
Text
id pubmed-4285328
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BlackWell Publishing Ltd
record_format MEDLINE/PubMed
spelling pubmed-42853282015-01-26 Correlation of HOXD3 promoter hypermethylation with clinical and pathologic features in screening prostate biopsies Chen, Leonard N Rubin, Rachel S Othepa, Eugide Cer, Caroline Yun, Elizabeth Agarwal, Raghunath P Collins, Brian T McGeagh, Kevin Pahira, John Bandi, Guarav Kowalczyk, Keith Kumar, Deepak Dritschilo, Anatoly Collins, Sean P Bostwick, David G Lynch, John H Suy, Simeng Prostate Original Articles BACKGROUND: Molecular markers that can discriminate indolent cancers from aggressive ones may improve the management of prostate cancer and minimize unnecessary treatment. Aberrant DNA methylation is a common epigenetic event in cancers and HOXD3 promoter hypermethylation (H3PH) has been found in prostate cancer. Our objective was to evaluate the relationship between H3PH and clinicopathologic features in screening prostate biopsies. METHODS: Ninety-two patients who underwent a prostate biopsy at our institution between October 2011 and May 2012 were included in this study. The core with the greatest percentage of the highest grade disease was analyzed for H3PH by methylation-specific PCR. Correlational analysis was used to analyze the relationship between H3PH and various clinical parameters. Chi-square analysis was used to compare H3PH status between benign and malignant disease. RESULTS: Of the 80 biopsies with HOXD3 methylation status assessable, 66 sets were confirmed to have cancer. In the 14 biopsies with benign disease there was minimal H3PH with the mean percentage of methylation reference (PMR) of 0.7%. In contrast, the HOXD3 promoter was hypermethylated in 16.7% of all cancers and in 50% of high risk tumors with an average PMR of 4.3% (P = 0.008). H3PH was significantly correlated with age (P = 0.013), Gleason score (P = 0.031) and the maximum involvement of the biopsy core (P = 0.035). CONCLUSIONS: H3PH is associated with clinicopathologic features. The data indicate that H3PH is more common in older higher risk patients. More research is needed to determine the role of this marker in optimizing management strategies in men with newly diagnosed prostate cancer. Prostate 74:714–721, 2014. © 2014 The Authors. The Prostate published by Wiley Periodicals, Inc. BlackWell Publishing Ltd 2014-05 2014-02-21 /pmc/articles/PMC4285328/ /pubmed/24847526 http://dx.doi.org/10.1002/pros.22790 Text en © 2014 The Authors. The Prostate published by Wiley Periodicals, Inc. http://creativecommons.org/licenses/by-nc/3.0/ This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Original Articles
Chen, Leonard N
Rubin, Rachel S
Othepa, Eugide
Cer, Caroline
Yun, Elizabeth
Agarwal, Raghunath P
Collins, Brian T
McGeagh, Kevin
Pahira, John
Bandi, Guarav
Kowalczyk, Keith
Kumar, Deepak
Dritschilo, Anatoly
Collins, Sean P
Bostwick, David G
Lynch, John H
Suy, Simeng
Correlation of HOXD3 promoter hypermethylation with clinical and pathologic features in screening prostate biopsies
title Correlation of HOXD3 promoter hypermethylation with clinical and pathologic features in screening prostate biopsies
title_full Correlation of HOXD3 promoter hypermethylation with clinical and pathologic features in screening prostate biopsies
title_fullStr Correlation of HOXD3 promoter hypermethylation with clinical and pathologic features in screening prostate biopsies
title_full_unstemmed Correlation of HOXD3 promoter hypermethylation with clinical and pathologic features in screening prostate biopsies
title_short Correlation of HOXD3 promoter hypermethylation with clinical and pathologic features in screening prostate biopsies
title_sort correlation of hoxd3 promoter hypermethylation with clinical and pathologic features in screening prostate biopsies
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4285328/
https://www.ncbi.nlm.nih.gov/pubmed/24847526
http://dx.doi.org/10.1002/pros.22790
work_keys_str_mv AT chenleonardn correlationofhoxd3promoterhypermethylationwithclinicalandpathologicfeaturesinscreeningprostatebiopsies
AT rubinrachels correlationofhoxd3promoterhypermethylationwithclinicalandpathologicfeaturesinscreeningprostatebiopsies
AT othepaeugide correlationofhoxd3promoterhypermethylationwithclinicalandpathologicfeaturesinscreeningprostatebiopsies
AT cercaroline correlationofhoxd3promoterhypermethylationwithclinicalandpathologicfeaturesinscreeningprostatebiopsies
AT yunelizabeth correlationofhoxd3promoterhypermethylationwithclinicalandpathologicfeaturesinscreeningprostatebiopsies
AT agarwalraghunathp correlationofhoxd3promoterhypermethylationwithclinicalandpathologicfeaturesinscreeningprostatebiopsies
AT collinsbriant correlationofhoxd3promoterhypermethylationwithclinicalandpathologicfeaturesinscreeningprostatebiopsies
AT mcgeaghkevin correlationofhoxd3promoterhypermethylationwithclinicalandpathologicfeaturesinscreeningprostatebiopsies
AT pahirajohn correlationofhoxd3promoterhypermethylationwithclinicalandpathologicfeaturesinscreeningprostatebiopsies
AT bandiguarav correlationofhoxd3promoterhypermethylationwithclinicalandpathologicfeaturesinscreeningprostatebiopsies
AT kowalczykkeith correlationofhoxd3promoterhypermethylationwithclinicalandpathologicfeaturesinscreeningprostatebiopsies
AT kumardeepak correlationofhoxd3promoterhypermethylationwithclinicalandpathologicfeaturesinscreeningprostatebiopsies
AT dritschiloanatoly correlationofhoxd3promoterhypermethylationwithclinicalandpathologicfeaturesinscreeningprostatebiopsies
AT collinsseanp correlationofhoxd3promoterhypermethylationwithclinicalandpathologicfeaturesinscreeningprostatebiopsies
AT bostwickdavidg correlationofhoxd3promoterhypermethylationwithclinicalandpathologicfeaturesinscreeningprostatebiopsies
AT lynchjohnh correlationofhoxd3promoterhypermethylationwithclinicalandpathologicfeaturesinscreeningprostatebiopsies
AT suysimeng correlationofhoxd3promoterhypermethylationwithclinicalandpathologicfeaturesinscreeningprostatebiopsies